Sarepta Therapeutics (SRPT) Continues Run as Eteplirsen Sentiment Remains High
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (Nasdaq: SRPT) shares are higher again on the session Friday, following a 14.3 percent gain on Thursday.
Shares have been strong since positive reports hit on August 15th for its DMD treatment, Eteplirsen.
Sentiment continued yesterday from this article.
Shares are up 13 of the last 16 sessions, or 14 of 17 if Sarepta closes higher Friday.
Shares have been strong since positive reports hit on August 15th for its DMD treatment, Eteplirsen.
Sentiment continued yesterday from this article.
Shares are up 13 of the last 16 sessions, or 14 of 17 if Sarepta closes higher Friday.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
